Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Celecoxib + Nirogacestat|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Celecoxib||Celecoxib is a COX-2 inhibitor that blocks inflammatory response and has anti-angiogenic and anti-proliferative activities (PMID: 31726219), which may lead to tumor growth inhibition (PMID: 17909047, PMID: 16740761).|
|Nirogacestat||PF-03084014|PF 03084014|PF03084014||Gamma secretase inhibitor 13||Nirogacestat (PF-03084014) is a small molecule that selectively binds to Gamma-secretase and inhibits its proteolytic activity on downstream targets including NOTCH receptor proteins, thus blocking NOTCH pathway activation in cancer (PMID: 28887726, PMID: 31211955).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|APC T1556Nfs*3||desmoid tumor||predicted - sensitive||Celecoxib + Nirogacestat||Case Reports/Case Series||Actionable||In a clinical case study, addition of Nirogacestat (PF-03084014) to Celecoxib treatment resulted in a reduction in tumor size and stable disease that was ongoing for at least 17 months in a pediatric patient with a desmoid tumor harboring APC T1556Nfs*3 (PMID: 32762028).||32762028|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|